Plus news on 340B, biosimilars, prior auth and more
Plus a good, if dispiriting, look at the state of access to a breakthrough postpartum depression pill
And a lot of Arnold Ventures-adjacent items, too
Plus more thinking on importation, 340B, and international pricing
And a Health Affairs paper adds further evidence that cost-sharing can be really, really bad for the public health
How Sanders & Co. deal with inhaler prices will be illuminating
Plus lots and lots about #JPM24, and why cost-plus is the new AI
Plus a lot more: data on launch price media coverage, CVS/Humira moves, a deep dive on Jan. 1 prices ...
And why 2024 will be the year of the launch price
Plus, in a twist on a Jan. 1 tradition, there's lot of attention on drug price *decreases*
And the Jan. 1 price-increase stories are starting to roll in
So keep those votes coming in ...
